Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

BACKGROUND: Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efficacy of combination treatment with osimertinib an...

Descripción completa

Detalles Bibliográficos
Autores principales: Miura, Satoru, Koh, Yasuhiro, Azuma, Koichi, Yoshioka, Hiroshige, Koyama, Kenichi, Teraoka, Shunsuke, Ishii, Hidenobu, Kibata, Kayoko, Ozawa, Yuichi, Tokito, Takaaki, Oyanagi, Jun, Shimokawa, Toshio, Kurata, Takayasu, Yamamoto, Nobuyuki, Tanaka, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808978/
https://www.ncbi.nlm.nih.gov/pubmed/36597021
http://dx.doi.org/10.1186/s12885-022-10467-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808978/
https://www.ncbi.nlm.nih.gov/pubmed/36597021
http://dx.doi.org/10.1186/s12885-022-10467-w

Ejemplares similares